医学
华登氏巨球蛋白血症
美罗华
弥漫性大B细胞淋巴瘤
淋巴浆细胞淋巴瘤
巨球蛋白血症
淋巴瘤
BCL6公司
化学免疫疗法
内科学
肿瘤科
胃肠病学
免疫学
B细胞
抗体
生发中心
多发性骨髓瘤
作者
Eirini Solia,Ioannis Ntanasis‐Stathopoulos,Efstathios Kastritis,Evangelos Terpos,Meletios Α. Dimopoulos,Maria Gavriatopoulou
出处
期刊:Cancer Diagnosis & Prognosis
[Anticancer Research USA Inc.]
日期:2024-01-02
卷期号:4 (1): 77-80
摘要
Background/Aim: Waldenström’s macroglobulinemia (WM) is a rare slow-growing B-cell lymphoma that is characterized by lymphoplasmacytic bone marrow infiltration and the production of monoclonal immunoglobulin M (IgM) paraprotein. In 5-10% of patients, WM undergoes transformation into diffuse large B-cell lymphoma (DLBCL), which is more aggressive, with poor prognosis and a low survival rate. Case Report: Α 69-year-old woman was diagnosed with WM in 2009. She received six cycles of chemoimmunotherapy and a remarkable remission was achieved. However, in 2013 the disease transformed into DLBCL. The patient received chemotherapy and after the completion of the first cycle of therapy, the disease was significantly minimized. At the end of the therapy, there was no evidence of disease, and the patient remains disease-free. The cytogenetic profile of the patient did not reveal expression of BCL2 apoptosis regulator, BCL6 transcription repressor, Epstein–Barr virus small RNA, syndecan 1 nor cyclin D1. According to a staging system based on the platelet count, lactate dehydrogenase and previous treatment for WM, the described patient was classified as being at intermediate risk with an expected 2-year survival probability of 47% after WM transformation into DLBCL. However, the patient unexpectedly exceeded these prognostic indications. Conclusion: The findings for this patient are of great interest compared with the existing literature which suggests that the survival and prognosis for patients with transformed DLBCL are not favorable.
科研通智能强力驱动
Strongly Powered by AbleSci AI